Pacira BioSciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Pacira BioSciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 12.1 times. Higher than 95% of Healthcare companies in United States.
- Debt Due Cover Ratio: Debt due within a year is covered 15.4 times by its yearly operating cash. Higher than 88% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
12.1×Over the last 3 years its own operating cash covered its investment spending (capex) 12.1 times.
Higher than 95% of Healthcare companies in United States.
Cash Locked Ratio
$36For every $100 of sales, $36 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $27 tied up three years earlier.
More money tied up than 76% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
−$15Sales grew 9% in 3 years, but profit fell: $15 less profit per $100 of extra sales.
Lower than 75% of Healthcare companies in United States.
Asset Productivity Ratio
+9% / -25%In 3 years sales changed by +9% while total assets changed by -25%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
15.4×Debt due within a year is covered 15.4 times by its yearly operating cash.
Higher than 88% of Healthcare companies in United States.
Cash Cushion Ratio
−12%Debt, after subtracting cash, equals 12% of its market value (net debt).
Lower than 80% of Healthcare companies in United States.
Tangible Assets Ratio
69%Of every $100 the company owns, $69 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 63% of Healthcare companies in United States.
Tangible Net Worth Ratio
44%Of every $100 of net worth, $44 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 56% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Pacira BioSciences, Inc. owes $0.46 for every $1 it owns. Pacira BioSciences, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
103.8Investors pay $103.8 for every $1 of Pacira BioSciences, Inc.'s yearly profit, higher than 91% of Healthcare companies in United States.
P/B ratio
2.16The share price is 2.16 times Pacira BioSciences, Inc.'s book value per share, lower than 55% of Healthcare companies in United States.
Market cap
$1.5 BThe total market value of all of Pacira BioSciences, Inc.'s shares at today's price (share price × number of shares), larger than 69% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$672 MWhat Pacira BioSciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$16.84Net worth divided by the number of shares. The share price of $36.34 is 2.2 times this, which is the P/B above.
Return on equity (ROE)
2.0%Pacira BioSciences, Inc. earned 2.0% on its shareholders' money over the last year, higher than 77% of Healthcare companies in United States.
Owes vs Owns
0.46×Pacira BioSciences, Inc. owes $0.46 for every $1 it owns (low), higher than 53% of Healthcare companies in United States.
Dividend yield
NonePacira BioSciences, Inc. does not currently pay a dividend.
Revenue growth
+4%Revenue rose 4% in the year to Dec 2025, and grew 3% a year on average over 3 years.
Profit growth
Back to profitPacira BioSciences, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
1.0%Pacira BioSciences, Inc. keeps $1 of every $100 of revenue as net profit.
Cash quality
21.6×Cash from Pacira BioSciences, Inc.'s business was 21.6× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
1.3×Pacira BioSciences, Inc.'s operating profit covered its interest costs 1.3 times in the year to Dec 2025.
Cash vs debt
Net debtPacira BioSciences, Inc. had $180 M more debt than cash (net debt) at Dec 2025.
Questions
What is Pacira BioSciences, Inc.'s P/E ratio?
Investors pay $103.8 for every $1 of Pacira BioSciences, Inc.'s yearly profit, higher than 91% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Pacira BioSciences, Inc.: $1.5 B ÷ $672 M (30 Jun 2026) = 2.2.
What is Pacira BioSciences, Inc.'s return on equity?
Pacira BioSciences, Inc. earned 2.0% on its shareholders' money over the last year, higher than 77% of Healthcare companies in United States.
How much does Pacira BioSciences, Inc. owe compared with what it owns?
Pacira BioSciences, Inc. owes $0.46 for every $1 it owns (low), higher than 53% of Healthcare companies in United States.
Does Pacira BioSciences, Inc. pay a dividend?
No. Pacira BioSciences, Inc. does not currently pay a dividend.
Is Pacira BioSciences, Inc.'s revenue growing?
Revenue rose 4% in the year to Dec 2025, and grew 3% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.